Bioxyne Delivers Australia's First Pharmaceutical Cannabis Gummies, Scales Up Manufacturing Capabilities
Bioxyne Delivers Australia's First Pharmaceutical Cannabis Gummies, Scales Up Manufacturing Capabilities
Australian life sciences and health products company Bioxyne Limited (ASX: BXN) announced Wednesday that its fully-owned subsidiary, Breathe Life Sciences (BLS), has successfully manufactured and delivered Australia's first pharmaceutical-grade cannabis edibles. These new gummies carry Good Manufacturing Practice (GMP) certification from the Therapeutic Goods Administration (TGA). This milestone marks a significant advancement in the domestic production and availability of medicinal marijuana products in Australia.
澳洲生命科学和健康产品公司Bioxyne Limited (ASX: BXN) 宣布,其全资子公司Breathe Life Sciences (BLS) 成功制造并交付了澳大利亚首批药用级大麻食品。这些新的软糖获得了澳洲药物管理局 (TGA) 颁发的良好生产规范 (GMP) 认证。这一里程碑标志着澳洲在国内生产和供应药用大麻产品方面的重大进展。
"BLS is the first Australian manufacturer to complete a commercial production run of pharmaceutical grade GMP-certified THC gummies," stated Sam Watson, founder & CEO of BLS and Managing Director of BXN. "As a leading Australian cannabis manufacturer, we are supplying our pharmaceutical goods to both domestic and international markets, using established relationships and existing supply channels."
"BLS是澳洲首家完成药品级 GMP 认证 THC 软糖的商业生产的制造商," BLS 创始人兼 CEO、BXN 董事长 Sam Watson 表示。"作为澳洋区领先的大麻制造商,我们向国内和国际市场供应我们的制药产品,利用已建立的关系和现有的供应渠道。"
In July 2024, BLS received deposits on purchase orders totaling approximately AU$2million ($1.35 million) for cannabis gummies, containing both cannabidiol (CBD) and/or delta-9-tetrahydrocannabinol (THC). According to the company's press release, this marks the first commercial sale of Australian-made edible cannabis products.
2024年7月,BLS 收到了总额约为20万澳元 ($135万美元) 的购买订单订金,用于含有大麻二酚 (CBD) 和/或 Δ-9-四氢大麻酚 (THC) 的软糖。根据公司的新闻稿,这标志着澳洲制造的可食用大麻产品的首次商业销售。
BLS has also signed a two-year manufacturing and supply agreement with one of Australia's largest cannabis companies, forecasted to generate a minimum of AU$28 million from the production of such edibles.
BLS 还与澳洲最大的大麻公司之一签署了为期两年的制造和供应协议,预计将从生产此类食品中赚取至少2800万澳元。
To meet the growing market demand for edible products, BLS is scaling up its gummy manufacturing capabilities from 2 million single doses per month to 6 million per month.
为应对可食用产品的不断增长的市场需求,BLS 正将其软糖的制造能力从每月200万份提高到每月600万份。
Read Also: Australian Cannabis Producers Eye European Market, Especially Germany And France, Marijuana And Menstrual Pain Study Underway
阅读更多:澳洲大麻生产商瞄准欧洲市场,尤其是德国和法国,研究表明大麻可以缓解月经疼痛
Market Growth Potential
市场增长潜力
Bioxyne highlighted that according to some estimates, the market for prescription cannabis edibles in Australia is expected to grow significantly in the near future, from approximately 1% of the ~AU$500 million per year Australian medical cannabis market in 2023 to more than 20% by 2030, which represents a potential AU$150 million per year opportunity.
Bioxyne 强调,根据一些估计,澳洲处方大麻可食用品市场未来预计将显著增长,从2023年约总值约为5亿澳元的澳洲医用大麻市场的1%增长到2030年的20%以上,这代表着每年1500万澳元的潜在机会。
"This is a significant milestone for Australian pharmaceutical manufacturing and the medical cannabis industry as a whole," said Jason Stephens, general manager of BLS Australia. "Australia is fast becoming a global medical cannabis hub and BLS is quickly becoming a substantial proponent of that. Our focus is building strong ties with our business customers and providing high-quality GMP-certified manufacturing services."
这是澳洲药品制造业和整个医疗大麻股行业的重要里程碑,BLS澳洲的总经理Jason Stephens表示:"澳大利亚正在迅速成为全球医疗大麻股中心,而BLS正在迅速成为这一中心的重要支持者。我们的重点是与我们的业务客户建立紧密关系,并提供高质量的GMP认证制造业务。"
Bioxyne is also a supplier of other alternative pharmaceutical goods such as psilocybin and MDMA to authorized prescribers and clinical trials in both domestic and international markets.
Bioxyne还是其他替代药品的供应商,如溴麦角啶和MDMA,供应给国内外授权的处方医师和临床试验。